Clinical uses of pet in neurology

Nuclear Medicine Communications

Volumn 21, Issue 3, 2000, Pages 237-240

  Barrington, S F ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEMENTIA; EPILEPSY; HUMAN; NEUROLOGIC DISEASE; REVIEW; SCINTISCANNING;

DEMENTIA; EPILEPSY; HUMANS; NERVOUS SYSTEM DISEASES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034152422     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200003000-00007     Document Type: Article

References (41)

1. Shorvon SD. Medical services for epilepsy. In: Richens A, Laidlaw J, Oxley J, eds. A textbook of epilepsy, 3rd edn. London: Churchill Livingstone, 1988: 611-630.
2. Crandall PH, Rausch R, Engel J. Preoperative indicators for optimal surgical outcome for temporal lobe epilepsy. In: Wieser HG, Elgar CE, eds. Presurgical evaluation of epileptics. Berlin: Springer, 1987: 325-334.
3. Engel Jr J, Henry TR, Risinger MW, Sutherling WW, Chugani HT. PET in relation to intracranial electrode evaluations. In: Theodore WH, ed. Surgical treatment of epilepsy. Epilepsy Res 1992; (suppl. 5): 111-120.
4. Alarcon G, Koutroumanidis M, Martin-Miguel MC, Binnie CD, Elwes RDC, Polkey CP. Topographic congruence of FDG PET and electrocorticographic abnormalities in temporal lobe epilepsy. Electroencephal Clin Neurophysiol (in press).
5. Koutroumanidis M, Barrington S, Agathonikou A et al. Interictal regional slow activity in temporal lobe epilepsy correlated with lateral temporal hypometabolism as imaged with FDG-PET: Neurophysiological and metabolic implications. J Neurol Neurosurg Psychiatr 1998; 65: 170-176.
6. Engel J, Brown WJ, Kuhl DE et al. Pathological findings underlying focal temporal lobe hypometabolism in partial epilepsy. Ann Neurol 1982; 12: 518-522.
7. Henry TR, Frey KA, Sackellares JC et al. in vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy. Neurology 1993; 43: 1998-2006.
8. Henry TR. Functional imaging with positron emission tomography. Epilepsia 1996; 37: 1141-1154.
9. Sadzot B. Neuroimaging in epilepsy: Is there a future for positron emission tomography? Epilepsia 1996; 37: 511-514.
10. Savic I, Persson A, Roland P et al. in vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988; 2: 863-866.
11. Savic I, Thorell JO, Roland P. 11C flumazenil positron emission tomography visualises frontal epileptogenic regions. Epilepsia 1995; 36: 1225-1232.
12. Spencer SS. The relative contributions of MRI, SPECT and PET imaging in epilepsy. Epilepsia 1994; 35(suppl. 6): S72-S89.
13. Rowe C. Nuclear medicine in the management of a patient with epilepsy. In: Murray IPC, Ell PJ, eds. Nuclear medicine in diagnosis and treatment. London: Churchill Livingstone, 1998: 651-663.
14. Manno EM, Sperling MR, Ding X et al. Predictors of outcome after anterior temporal lobectomy: Positron emission tomography. Neurology 1994; 44: 2331-2336.
15. Theodore WH, Sato S, Kufta C et al. Temporal lobectomy for uncontrolled seizures: The role of positron emission tomography. Ann Neurol 1992; 32: 789-794.
16. Swartz BE, Tomiyasu U, Delgado-Escueta AV, Mandelkern M, Khousari A. Neuroimaging in temporal lobe epilepsy: Test sensitivity and relationships to pathological and postoperative outcome. Epilepsia 1992; 33: 624-634.
17. Savic I, Altshuler L, Passaor E, Baxter I, Engel Jr J. Localised cerebellar hypometabolism in patients with complex partial seizures. Epilepsia 1996; 37: 781-787.
18. Henry TR, Mazziotta JC, Engel J et al. Quantifying interictal metabolic activity in human temporal lobe epilepsy. J Cereb Blood Flow Metab 1990; 10: 748-757.
19. Barrington SF, Koutroumanidis M, Agathonikou A et al. Clinical value of ‘ictal’ FDG-PET and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 1998; 39: 753-766.
20. Shen W, Lee BI, Park HM et al. HIDPM SPECT brain imaging in the presurgical evaluation of patients with intractable seizures. J Nucl Med 1990; 31: 1280-1284.
21. Newton MR, Berkovic SF, Austin MC et al. Ictal, post-ictal and interictal single photon emission tomography in the lateralisation of temporal lobe epilepsy. Eur J Nucl Med 1994; 21: 1067-1071.
22. Rowe CC, Berkovic SF, Austin MC. Patterns of postictal cerebral blood flow in temporal lobe epilepsy: Qualitative and quantitative analysis. Neurology 1991; 41: 1096-1103.
23. Chugani HT, Shields WD, Shewmon DA et al. Infantile spasms: PET identifies focal cortical dysgenesis in cryptogenic cases for treatment. Ann Neurol 1990; 27: 406-413.
24. Cummings TJ, Chugani DC, Chugani HT. Positron emission tomography in pediatric epilepsy. Neurosurg Clin Nth Am 1995; 6: 465-472.
25. Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Sem Nucl Med 1992; 4: 233-246.
26. Herholz K, Perani D, Gilardi MCG et al. Comparability of FDG PET studies in probable Alzheimer’s disease. J Nucl Med 1993; 35: 7-15.
27. Jobst KA, Hindley NJ, King E, Smith AD. The diagnosis of Alzheimer’s disease: A question of image? J Clin Psychiatr 1994; 55(suppl. 11): 22-31.
28. Grady CL, Haxby JV, Horwitz B et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol 1988; 10: 576-596.
29. Small GW, Leiter F. Neuroimaging for the diagnosis of dementia. J Clin Psychiatr 1998; 59(suppl. 11): 4-7.
30. Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AAF. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996; 47: 462-466.
31. Rottenberg DA, Sidtis JJ, Strother SC et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996; 37: 1133-1141.
32. Kuhl DE, Phelps ME, Markham CH et al. Cerebral metabolism and atrophy in Huntingdon’s disease determined by F-18 FDG and computed tomographic scan. Ann Neurol 1982; 12: 425-434.
33. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntingdon’s disease. Brain 1990; 113: 1405-1423.
34. DiChiro G, De La Paz RL, Brooks RA et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
35. Alavi JB, Alavi A, Chawluk J et al. Positron emission tomography in patients with glioma. Cancer 1988; 62: 1074-1078.
36. Delbeke D, Meyerowitz C, Lapidus R et al. Optimal cutoff levels of 18F fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumours with PET. Radiology 1995; 195: 47-52.
37. Valk P, Budinger T, Levin V et al. PET of malignant cerebral tumors after interstitial brachytherapy. J Neurosurg 1988; 69: 830-838.
38. Ogawa T, Shisodo F, Kanno I et al. Cerebral glioma: Evaluation with methionine PET. Radiology 1993; 186: 45-53.
39. Ogawa T, Hatazawa J, Inugami A et al. Carbon-11-methionine PET evaluation of intracerebral hematoma: Distinguishing neoplastic from non-neoplastic hematoma. J Nucl Med 1995; 36: 2175-2179.
40. Francavilla TL, Miletich RS, DiChiro G. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989; 24: 1-5.
41. O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the HIV positive patient. J Nucl Med 1997; 38: 1575-1583.